NightHawk’s Scorpius BioManufacturing Subsidiary Announces the Promotion of Joe Payne to President and Chief Operating Officer
01 Février 2024 - 2:00PM
NightHawk Biosciences (NYSE American: NHWK) (“NightHawk” or the
“Company”), an integrated contract development and manufacturing
organization (CDMO), today announced the promotion of Joe Payne to
President and Chief Operating Officer (COO) of its Scorpius
BioManufacturing subsidiary.
Payne joined Scorpius in 2023 as VP of Quality and Regulatory
Affairs. With a biopharma and pharmaceutical career spanning over
20 years, Payne’s recent experience includes leadership roles at
CDMOs Tergus Pharma and Alcami Corporation. He has participated in
40+ regulatory inspections and has extensive knowledge of global
regulatory agency requirements. In his role as President and COO,
Payne will oversee quality, manufacturing, process sciences, and
commercial operations.
Jeff Wolf, CEO of NightHawk Biosciences, commented, “Joe has
seen nearly 100 different pharmaceutical facilities and has
interacted with thousands of industry professionals at all levels.
His expertise and experience will greatly benefit Scorpius during
its next phase of growth. Joe has deep experience in developing and
implementing quality production processes within large and small
CDMO’s. Joe’s appointment reflects our focus on quality
biomanufacturing throughout our organization. I’m confident Joe
will ensure our clients have the smoothest path from the lab to the
clinic to commercialization.”
Joe Payne further noted, “When I joined Scorpius in 2023, I was
focused on building a robust quality operation. I was impressed by
the team’s commitment, from the leadership all the way to our
floor-level operators. I’m truly grateful for the faith that Jeff,
the board, and the entire organization have placed in me, and I
look forward to working with current and future clients to bring
their biologic innovations to patients as efficiently and safely as
possible.”
Mr. Wolf, Mr. Payne and the Scorpius commercial team will be at
DCAT Week in New York City on March 18-21 to meet with clients and
prospects about analytical testing, process development, and
manufacturing services.
NightHawk Biosciences, Inc.
NightHawk Biosciences, through its Scorpius BioManufacturing
subsidiary, is an integrated contract development and manufacturing
organization (CDMO) focused on rapidly advancing biologic programs
to the clinic and beyond. Scorpius offers a broad array of
analytical testing, process development, and manufacturing services
to pharmaceutical and biotech companies at its state-of-the-art
facilities in San Antonio, TX. With an experienced team and new,
purpose-built U.S. facilities, Scorpius is dedicated to transparent
collaboration and flexible, high-quality biologics
biomanufacturing. For more information, please visit:
www.nighthawkbio.com or www.scorpiusbiologics.com.
Forward-Looking Statement
This release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995. In
some cases forward-looking statements can be identified by
terminology such as "may," "should," "potential," "continue,"
"expects," "anticipates," "intends," "plans," "believes,"
"estimates," and similar expressions, and include statements such
Mr. Payne’s contribution to Scorpius including his expertise and
experience greatly benefitting Scorpius during its next phase of
growth and Mr. Payne ensuring clients have the smoothest path from
the lab to the clinic to commercialization.. Important factors that
could cause actual results to differ materially from current
expectations include, among others, the Company’s ability to derive
the contributions to Scorpius anticipated from Mr. Payne, the
ability to generate future revenue from manufacturing contracts,
the Company’s ability to continue its strategy and to grow revenue,
leverage fixed costs and achieve long-term profitability; the
Company’s ability to create substantial shareholder value as a
pure-play CDMO in an underserved marketplace, the Company’s
financing needs, its cash balance being sufficient to sustain
operations and its ability to raise capital when needed, the
ability to obtain regulatory approval or to comply with ongoing
regulatory requirements, regulatory limitations relating to the
Company’s ability to successfully promote its services and compete
as a pure- play CDMO, and other factors described in the Company’s
annual report on Form 10-K for the year ended December 31, 2022,
subsequent quarterly reports on Form 10-Qs and any other filings
the Company makes with the SEC. The information in this
presentation is provided only as of the date presented, and the
Company undertakes no obligation to update any forward-looking
statements contained in this presentation on account of new
information, future events, or otherwise, except as required by
law.
Media and Investor Relations ContactDavid
Waldman+1 919 289 4017investorrelations@nighthawkbio.com
Nighthawk Biosciences (AMEX:NHWK)
Graphique Historique de l'Action
De Mar 2024 à Avr 2024
Nighthawk Biosciences (AMEX:NHWK)
Graphique Historique de l'Action
De Avr 2023 à Avr 2024